File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jad.2023.10.074
- Scopus: eid_2-s2.0-85173878795
- PMID: 37838264
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Multimorbidity representation in randomized controlled trials of selective serotonin reuptake inhibitors: A systematic analysis of published trials
Title | Multimorbidity representation in randomized controlled trials of selective serotonin reuptake inhibitors: A systematic analysis of published trials |
---|---|
Authors | |
Keywords | Antidepressant Bibliometric analysis Comorbidity Depression Mental health Psychopharmacology |
Issue Date | 1-Jan-2024 |
Publisher | Elsevier |
Citation | Journal of Affective Disorders, 2024, v. 344, p. 261-266 How to Cite? |
Abstract | Background: Previous research has suggested a bidirectional relationship between multimorbidity and depression, with an increasing number of people living with both conditions. Therefore, we investigated how multimorbidity is represented in randomized controlled trials (RCT) of selective serotonin reuptake inhibitors (SSRI). Methods: We conducted a comprehensive keyword search in PubMed, Cochrane Central Library, PsycINFO, and EMBASE for RCTs published in 2011 or later. Multimorbidity representation was categorized into ‘inclusion’ or ‘exclusion’ within the study with studies including multimorbidity further categorized as conducting ‘multivariable adjustment’ or ‘effect modification/stratification’. Logistic regression was used to examine the association of different study characteristics with multimorbidity representation among the studies. Results: In total, 183 trials were included for analysis. Nearly 60 %, i.e., 106 trials, excluded people with multimorbidity, and only four studies either conducted multivariable adjustment for baseline health conditions or examined potential effect modifications from multimorbidity. Studies based in Asia had significantly increased odds of multimorbidity exclusion compared to North America (odds ratio 3.18, 95 % confidence interval 1.09–1.39). A larger sample size was estimated to be associated with greater odds of conducting effect modification analysis for multimorbidity (odds ratio 1.006, 95 % confidence interval 1.001–1.011). Limitations: Studies are limited to published, English-language studies where the short timespan may hinder the visibility of the multimorbidity trend. Conclusions: Only a minority of RCTs on SSRIs considered multimorbidity within their study design. As both mental health awareness and multimorbidity are becoming increasingly ubiquitous within the global population, it is important for future studies to consider multimorbidity. |
Persistent Identifier | http://hdl.handle.net/10722/348345 |
ISSN | 2023 Impact Factor: 4.9 2023 SCImago Journal Rankings: 2.082 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lum, Dawn Hei | - |
dc.contributor.author | Choi, Mandy Man | - |
dc.contributor.author | Cheung, Jacky On Hei | - |
dc.contributor.author | Ng, Dora Wai Yee | - |
dc.contributor.author | Leung, Janice Ching Nam | - |
dc.contributor.author | Zhou, Lingyue | - |
dc.contributor.author | Lai, Francisco Tsz Tsun | - |
dc.date.accessioned | 2024-10-09T00:30:55Z | - |
dc.date.available | 2024-10-09T00:30:55Z | - |
dc.date.issued | 2024-01-01 | - |
dc.identifier.citation | Journal of Affective Disorders, 2024, v. 344, p. 261-266 | - |
dc.identifier.issn | 0165-0327 | - |
dc.identifier.uri | http://hdl.handle.net/10722/348345 | - |
dc.description.abstract | <p>Background: Previous research has suggested a bidirectional relationship between multimorbidity and depression, with an increasing number of people living with both conditions. Therefore, we investigated how multimorbidity is represented in randomized controlled trials (RCT) of selective serotonin reuptake inhibitors (SSRI). Methods: We conducted a comprehensive keyword search in PubMed, Cochrane Central Library, PsycINFO, and EMBASE for RCTs published in 2011 or later. Multimorbidity representation was categorized into ‘inclusion’ or ‘exclusion’ within the study with studies including multimorbidity further categorized as conducting ‘multivariable adjustment’ or ‘effect modification/stratification’. Logistic regression was used to examine the association of different study characteristics with multimorbidity representation among the studies. Results: In total, 183 trials were included for analysis. Nearly 60 %, i.e., 106 trials, excluded people with multimorbidity, and only four studies either conducted multivariable adjustment for baseline health conditions or examined potential effect modifications from multimorbidity. Studies based in Asia had significantly increased odds of multimorbidity exclusion compared to North America (odds ratio 3.18, 95 % confidence interval 1.09–1.39). A larger sample size was estimated to be associated with greater odds of conducting effect modification analysis for multimorbidity (odds ratio 1.006, 95 % confidence interval 1.001–1.011). Limitations: Studies are limited to published, English-language studies where the short timespan may hinder the visibility of the multimorbidity trend. Conclusions: Only a minority of RCTs on SSRIs considered multimorbidity within their study design. As both mental health awareness and multimorbidity are becoming increasingly ubiquitous within the global population, it is important for future studies to consider multimorbidity.</p> | - |
dc.language | eng | - |
dc.publisher | Elsevier | - |
dc.relation.ispartof | Journal of Affective Disorders | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Antidepressant | - |
dc.subject | Bibliometric analysis | - |
dc.subject | Comorbidity | - |
dc.subject | Depression | - |
dc.subject | Mental health | - |
dc.subject | Psychopharmacology | - |
dc.title | Multimorbidity representation in randomized controlled trials of selective serotonin reuptake inhibitors: A systematic analysis of published trials | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jad.2023.10.074 | - |
dc.identifier.pmid | 37838264 | - |
dc.identifier.scopus | eid_2-s2.0-85173878795 | - |
dc.identifier.volume | 344 | - |
dc.identifier.spage | 261 | - |
dc.identifier.epage | 266 | - |
dc.identifier.eissn | 1573-2517 | - |
dc.identifier.issnl | 0165-0327 | - |